Clinical trials: Viral Reactivation
Hepatocellular Carcinoma
Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study
Immune checkpoint inhibitor (ICI), including programmed cell death protein-1 (PD-1) inhibitor or programmed cell death-Ligand 1 (PD-L1) inhibitor , is recommended to treat advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT04680598
- Testing
- ICI, Antiviral Prophylaxis
- Where
- 4 sites in China
- Volunteers
- 800 people
- Sponsor
- Sun Yat-sen University
Lymphoma, Chronic Hepatitis B
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy
Previous studies dealt with patients who maintained antiviral drugs for 2 ~ 6 months after final chemotherapy and they revealed that many of the patients who stopped preemptive antiviral drug within 6 months experienced viral…
- Trial name
- NCT02056548
- Volunteers
- 126 people
- Sponsor
- Seoul St. Mary's Hospital
Long COVID-19, Long COVID
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19…
- Trial name
- RECOVER-VITAL (NCT05965726)
- Testing
- Paxlovid, Ritonavir
- Where
- United States
- Volunteers
- 964 people
- Sponsor
- Kanecia Obie Zimmerman
HIV Infections
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors
This study evaluated the effects of tamoxifen exposure in combination with vorinostat on viral reactivation among HIV-1 infected post-menopausal women with virologic suppression on antiretroviral therapy (ART), when compared to…
- Trial name
- NCT03382834
- Testing
- Tamoxifen, Vorinostat, Antiretroviral drugs
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Biological and Clinical Efficacy of Shingrix in Patients With CLL
This is a biological study. Patients who are eligible to receive Shingrix through the Italian National Health System will be invited to participate in the study.
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL-like MBL, Varicella-zoster Virus Reactivation
- Trial name
- NCT06364033
- Testing
- serologic response evaluation
- Where
- Italy
- Volunteers
- 312 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
HIV I Infection
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs.
- Trial name
- REDUC (NCT02092116)
- Testing
- Romidepsin, Vacc-4x, rhuGM-CSF
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Bionor Immuno AS
Hematologic Diseases
Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells
The purpose of this study is to assess the human herpes virus reactivation 6 post autologous stem cells in 196 patients. The aim of our study was to describe the incidence of reactivation of HHV-6 in patients requiring autologous…
- Trial name
- VIRAUTO6 (NCT02090803)
- Where
- 3 sites in France
- Volunteers
- 189 people
- Sponsor
- Institut de Cancérologie de la Loire
Rheumatoid Arthritis, Hepatitis B Reactivation
Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients
Antiviral prophylaxis can prevent the risk of biologic agents-associated HBV reactivation in hepatitis B inactive carriers and patients with past HBV infection
- Conditions
- Rheumatoid Arthritis, Hepatitis B Reactivation, Exposure to Hepatitis B Virus
- Trial name
- NCT01907230
- Testing
- Entecavir
- Where
- Taiwan
- Volunteers
- 115 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
BK Virus Nephropathy, Risk Factor
Evaluation of Renal Pretransplant Serology for BK Virus on the Risk of Post-transplant Viral Reactivation
Due to the increasing importance of BKV infection on the survival of kidney transplants, a better knowledge, in the pretransplant phase, of the risk factors leading to viral reactivation could allow the follow-up physician to be…
- Conditions
- BK Virus Nephropathy, Risk Factor, Kidney Transplantation
- Trial name
- BKSEREIN (NCT04506060)
- Testing
- serum withdrawal
- Where
- France
- Volunteers
- 378 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
HIV Infection, Herpes Simplex
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.
Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical and epidemiologic evidence show the role of HSV in increasing HIV infectiousness.
- Conditions
- HIV Infection, Herpes Simplex, Sexually Transmitted Diseases
- Trial name
- NCT00378976
- Testing
- valacyclovir
- Where
- Peru
- Volunteers
- 20 people
- Sponsor
- University of Washington
Hepatitis B Virus, Allograft
Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting
The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.
- Conditions
- Hepatitis B Virus, Allograft, Hematological Malignancies
- Trial name
- NCT00876148
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT)
Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation
This study aims to evaluate the clinical performance of a novel microRNA-based detection platform, SE-SPTM-PCR, for identifying cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), CMV Reactivation, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Trial name
- SESPTM-CMV (NCT07181330)
- Testing
- SE-SPTM-PCR microRNA assay
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ting YANG
HBV (Hepatitis B Virus), HIV Infection
Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients With HIV-1
The primary objective of the present project will be to investigate the risk of HBV reactivation (from virological reactivation to overt HBV infection) in HIV-1 carriers with occult HBV infection (OBI, is characterized by the…
- Trial name
- OBILART (NCT06728917)
- Where
- 3 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Non-Hodgkin Lymphoma, Hepatitis B Reactivation
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.
- Trial name
- NCT01914744
- Testing
- Entecavir, Lamivudine
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
Genital Herpes
A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
We propose to study the episode rate, duration, and quantity of HSV-2 genital shedding in patients taking standard, FDA approved, CDC recommended doses of acyclovir (400 mg PO BID) for HSV-2 suppression compared to taking no…
- Trial name
- NCT00723229
- Testing
- acyclovir
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
Hepatitis B
A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy
Liver diseases due to hepatitis B reactivation are serious causes of morbidity and mortality in hepatitis B infected patients treated with chemotherapy.
- Trial name
- NCT00489151
- Testing
- adefovir dipivoxil, lamivudine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hospital Authority, Hong Kong
HBV Reactivation, HSCT
HBV Reactivation Prediction Model in Allo-HSCT
Hepatitis B virus (HBV) reactivation is a serious complication after allogeneic haematopoietic stem cell transplantation (allo-HSCT), particularly in patients with resolved HBV infection (HBsAg-negative, anti-HBc-positive).
- Trial name
- HBV-post HSCT (NCT07644026)
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 300 people
- Sponsor
- Xiao Hui Zhang
HIV-1-infection, Hiv
Studying Topiramate for Re-Activating the HIV-1 Reservoir
Even with current HIV treatments, HIV is still a lifelong disease because it hides in some long-lasting cells in the body. One of the strategies to find a cure for HIV works by finding the virus in these cells, making it visible…
- Conditions
- HIV-1-infection, Hiv, HIV Infections, HIV I Infection
- Trial name
- STAR (NCT06282783)
- Testing
- Topiramate
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Erasmus Medical Center
EBV Infection, CMV Infection
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Subjects have a type of blood cell cancer, other blood disease or a genetic disease for which they received a stem cell transplant.
- Conditions
- EBV Infection, CMV Infection, Adenoviral Infection
- Trial name
- EAP CHALLAH (NCT01945619)
- Testing
- Trivirus-Specific CTLs
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation
HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR
Human cytomegalovirus (HCMV) infection is one of the most common and serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Virus Reactivation, Graft vs Host Disease
- Trial name
- HSCT-HCMV01 (NCT07210242)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Ting YANG